Long COVID Clinical Trial
— BLENDOfficial title:
A Pilot and Feasibility Study of a Web-based Platform to Improve Physical Function, Nutrition, and Mindfulness in Patients With Long COVID
Patients with COVID-19 may experience prolonged physical and psychological symptoms after weeks or months of the infection. This may be caused by a combination of factors including poor nutrition, low physical activity, and lack of emotional support. Leading to poor overall health and low quality of life. This evidence indicated that people with long COVID-19 need a personalized intervention. Our objective is to determine if the use of an online application that is based on preventive self-care and that includes nutrition and mindfulness will be feasible to use for patients with long COVID.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2024 |
Est. primary completion date | October 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged = 18 years. - COVID diagnosed (PCR positivity) >12 weeks at time of screening and have persistent symptoms. - Body mass index (BMI) >18.5kg/m2 and < 35 kg/m2. - People with long COVID syndrome diagnosis enrolled in the Kaye Edmonton Clinic. - Have mild to moderate long COVID syndrome (Based on the Post COVID-19 Functional Status Scale from 0-3). Exclusion Criteria: - Patients with severe mobility impairment (People without sufficiently mobile to come to the study centre). - Diagnosis of severe mental health disorders (e.g., depression, anxiety, eating disorders). - Individuals with pacemakers or other internal electrical medical devices. - Suffer from claustrophobia. - Pregnancy or lactation. - No internet access. - Not able to understand and communicate in English. - Major visual or hearing impairment or other serious illness that would preclude participation. - Living in assisted living situations or a nursing home. - Individuals who fell more than 3 times in the last month. Because of the risk of doing a physical activity unsupervised. - Not willing to make a change in their lifestyle (Readiness to change). |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | Revive Wellness Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility (defined by recruitment, adherence, and retention). | The proportion of participants that agreed to participate, the engagement in the platform (login), participants who complete both visits | Baseline, week 8 | |
Secondary | Changes in quality of life parameters | Changes in scores of quality of life assessed by EuroQol 5-level EQ-5D. | Baseline, week 8 | |
Secondary | Changes in fat mass | Changes in fat mass (kg) using bioelectrical impedance analysis | Baseline, week 8 | |
Secondary | Changes in lean mass | Changes in lean mass (kg) using bioelectrical impedance analysis | Baseline, week 8 | |
Secondary | Changes in muscle cross sectional area | Changes in muscle cross sectional area (cm2) using an ultrasound | Baseline, week 8 | |
Secondary | Changes in dietary intake | Changes in diet quality assessed by dietary intake assessed by Automated Self-Administered 24-hour dietary assessment tool and analysed with Canadian version of the Healthy Eating Index | Baseline, week 8 | |
Secondary | Changes in mindfulness with Mental health questionnaire from the Symptom Burden Questionnaire for Long COVID | Changes in mindfulness assessed by Mental health questionnaire from the Symptom Burden Questionnaire for Long COVID (SBQ-LC). 9-item measure. Scores are to 0-100 linear. Higher scores indicate greater symptom burden. | Baseline, week 8 | |
Secondary | Changes in self-efficacy assessed with Patient-Reported Outcomes Measurement Information System | Changes in self-efficacy for managing chronic conditions with of 8-item questionnaire that is based on a Patient-Reported Outcomes Measurement Information System (PROMIS).The total raw score (ranging from 8 to 40) will be transferred to a T-score. A mean of 50 and a standard deviation (SD) of 10 will be the average. A higher PROMIS T-score indicates that the respondent has greater self-efficacy for managing their emotions than the general chronic condition population. | Baseline, week 8 | |
Secondary | Changes in physical function | Changes in physical function assessed by handgrip strength | Baseline, week 8 | |
Secondary | Changes in physical performance | Changes in physical performance assessed by 6-minute walk test | Baseline, week 8 | |
Secondary | Changes in physical activity (daily activities subscale) by the Symptom Burden Questionnaire for Long COVID. | Changes in physical activity assessed by Daily Activities Symptom Burden Questionnaire for Long COVID (SBQ-LC). Raw scores (ranging from 0 to 24) will be converted to 0-100 linear scores with conversion tables. Higher scores indicate greater symptom burden. | Baseline, week 8 | |
Secondary | Changes in physical activity using the International Physical Activity Questionnaire | Changes in physical activity assessed by International Physical Activity Questionnaire (IPAQ). This questionnaire collects information about three specific types of physical activity: walking, moderate-intensity activities and vigorous intensity activities. To compute the total score, measures of frequency (measured in days per week) and duration (time per day) are needed. We will use this information to compare over time. | Baseline, week 8 | |
Secondary | Changes in resting energy expenditure | Changes in resting energy expenditure assessed by a metabolic cart (indirect calorimetry) | Baseline, week 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
Enrolling by invitation |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
Enrolling by invitation |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
Recruiting |
NCT05855369 -
Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
|
Phase 2/Phase 3 | |
Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 |